Volume 63, Issue 4 pp. 524-525

Clinical Correspondence

Dupilumab for moderate–severe atopic dermatitis: a real-world, single-center retrospective study of 122 patients in the United States

Veronica K. Emmerich MD,

Veronica K. Emmerich MD

Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA

Search for more papers by this author

Josiah A. Williams MD,

Josiah A. Williams MD

orcid.org/0000-0002-8304-4249

Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA

Search for more papers by this author

Matthew L. Hrin MD,

Corresponding Author

Matthew L. Hrin MD

[email protected]

orcid.org/0000-0002-2769-3156

Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA

Search for more papers by this author

Steven R. Feldman MD, PhD,

Steven R. Feldman MD, PhD

Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA

Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA

Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA

Department of Dermatology, University of Southern Denmark, Odense, Denmark

Search for more papers by this author

Lindsay C. Strowd MD,

Lindsay C. Strowd MD

Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA

Search for more papers by this author

Veronica K. Emmerich MD,

Veronica K. Emmerich MD

Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA

Search for more papers by this author

Josiah A. Williams MD,

Josiah A. Williams MD

orcid.org/0000-0002-8304-4249

Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA

Search for more papers by this author

Matthew L. Hrin MD,

Corresponding Author

Matthew L. Hrin MD

[email protected]

orcid.org/0000-0002-2769-3156

Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA

Search for more papers by this author

Steven R. Feldman MD, PhD,

Steven R. Feldman MD, PhD

Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA

Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA

Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA

Department of Dermatology, University of Southern Denmark, Odense, Denmark

Search for more papers by this author

Lindsay C. Strowd MD,

Lindsay C. Strowd MD

Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA

Search for more papers by this author

First published: 13 December 2023

https://doi.org/10.1111/ijd.16973

Citations: 1

Reviewed and approved by Wake Forest University Health Sciences IRB00065482.

Conflict of interest: Dr. Steven Feldman has received research, speaking, and/or consulting support from a variety of companies including Galderma, GSK/Stiefel, Almirall, Leo Pharma, Baxter, Boeringer Ingelheim, Mylan, Celgene, Pfizer, Valeant, Taro, Abbvie, Cosmederm, Anacor, Astellas, Janssen, Lilly, Merck, Merz, Novartis, Regeneron, Sanofi, Novan, Parion, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate, and National Psoriasis Foundation. He is the founder and majority owner of www.DrScore.com and founder and part owner of Causa Research, a company dedicated to enhancing patients' adherence to treatment. Dr. Lindsay Strowd has received research, speaking, and/or consulting support from Galderma, Sanofi, Actelion, and Pfizer. The remaining authors have no conflicts to disclose.

Funding source: None.

Share a link

Email
Wechat
Bluesky

No abstract is available for this article.

References

1Silverberg JI, Kantor R. The role of interleukins 4 and/or 13 in the pathophysiology and treatment of atopic dermatitis. Dermatol Clin. 2017; 35(3): 327–334. https://doi.org/10.1016/j.det.2017.02.005
10.1016/j.det.2017.02.005
CAS PubMed Web of Science® Google Scholar
2Silverberg JI, Simpson EL, Ardeleanu M, Thaçi D, Barbarot S, Bagel J, et al. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials. Br J Dermatol. 2019; 181(1): 80–87. https://doi.org/10.1111/bjd.17791
10.1111/bjd.17791
CAS PubMed Web of Science® Google Scholar
3Paller AS, Bansal A, Simpson EL, Boguniewicz M, Blauvelt A, Siegfried EC, et al. Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: post-hoc analyses from a randomized clinical trial. Am J Clin Dermatol. 2020; 21(1): 119–131. https://doi.org/10.1007/s40257-019-00478-y
10.1007/s40257-019-00478-y
PubMed Web of Science® Google Scholar
4Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021; 84(1): 139–147. https://doi.org/10.1016/j.jaad.2020.08.051
10.1016/j.jaad.2020.08.051
CAS PubMed Web of Science® Google Scholar
5Kamata M, Tada Y. A literature review of real-world effectiveness and safety of dupilumab for atopic dermatitis. JID Innov. 2021; 1(3):100042. https://doi.org/10.1016/j.xjidi.2021.100042
10.1016/j.xjidi.2021.100042
PubMed Google Scholar

Citing Literature

Volume63, Issue4

April 2024

Pages 524-525

Dupilumab for moderate–severe atopic dermatitis: a real-world, single-center retrospective study of 122 patients in the United States

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Dupilumab for moderate–severe atopic dermatitis: a real-world, single-center retrospective study of 122 patients in the United States

References

Citing Literature

References

Related

Information